Beta Bionics, Inc. Overview
Pro stress-test →Beta Bionics is a commercial-stage medical device company that designs, develops, and commercializes solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company offers the iLet Bionic Pancreas, an insulin delivery device for treating type 1 diabetes in adults and children six years of age and older.
Strategic Profile
Pro stress-test →Beta Bionics has established itself as a key leader in the durable insulin pump market, as evidenced by sales force productivity, pharmacy channel coverage, and gross margin profile. The company achieved 54% net sales growth in 2025 to $100.3M and more than doubled its installed user base, while guiding 2026 revenue to $130–$135M.
Competitive Landscape
Pro stress-test →Competitors in the insulin pump and diabetes management space include Tandem Diabetes Care and other durable medical equipment manufacturers. Beta Bionics differentiates through its automated bionic pancreas technology and expanding multi-channel reimbursement strategy, positioning it as an emerging leader in the growing insulin pump market.
Industry Context
Beta Bionics, Inc. operates in Medical Devices - Diabetes Management & Insulin Delivery Systems.
Key facts
Headquarters: Irvine, United States · Revenue: $100.3M (2025) · Market cap: $1.34B